All In Biotech

Drug Trial Radar · NCT05914805

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 762 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

762

Actual

Start

Aug 17, 2023

Primary completion

Jul 16, 2025

Study completion Jul 16, 2025

Sponsor

Lead sponsor
Cassiopea SpAIndustry
Sponsor type
Industry
Collaborators
Ergomed PLC; Pharmapace Inc; Canfield Scientific Inc.; ICON Clinical Research
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects. Within this study, the Clascoterone solution will be compared to a placebo. The study has 2 parts: Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months. Part 2 will see the long-term safety and efficacy of the Clascoterone solution compared to placebo for additional 6 months in subjects defined as ''responders'' in Part 1. A responder is defined as someone who have responded to the study drug, based on research data. Part 1 of the study is double-blind, meaning that neither the subject nor the study doctor knows which treatment subject is receiving. Part 2 of the study is single-blind and only the study doctor doing the study knows which treatment subject is receiving. Part 1 of the study will start with baseline visit during which subjects will be randomly assigned (by chance) in ratio 2:1 to apply either Clascoterone or placebo solution to their balding areas of the scalp. Subjects will have 5 clinic visits and 2 follow-up phone calls during 6 months of Part 1 duration. Subjects identified as Part 1 responders at Month 6 visit will be again randomly assigned in ratio 2:1 to receive either study drug or placebo. Part 2 of the study will consist of 2 additional clinic visits and treatment will last for further 6 months. Each subject will have also an end of study visit one month after the study drug treatment has been completed or discontinued (it will be one month after end of Part 1 for not responder subjects). For those subjects who complete the whole study (Part 1 and Part 2), the total duration of the study will be about 14 months, with 12 months of treatment with a total of eight clinic visits and two phone calls. Subjects taking part in this study will have the medical tests or procedures described below. * They will be asked about their previous medical history and current medications. * A brief physical examination will be performed. * Vital signs, weight and height will be measured. * Electrocardiograms will be performed. * Subject's scalp will be checked for any signs of irritation. * Two different types of photos will be taken during this study: "global photos", i.e. general photos of the subject's scalp and "macro photos", i.e. close up photos of a region of the subject's scalp. Global photos will be taken to help the subject and the study doctor to assess whether there has been a change in subject's hair growth. Macro photos will be used to count the number of hairs in a region of the subject's scalp and measure other properties of the hair (hair width and hair darkness). * Blood draws and urine sample collection for safety laboratory tests. * Subject will be asked to complete, on site, the following two questionnaires: * Cosmetic Evaluation - a couple of cosmetic questions on acceptability and how easy the study drug is to use. * Male Androgenetic Alopecia Questionnaire - some questions about subject's hair assessment. Eligible subjects will be given a supply of the study drug and shown how to use and store it. The first study drug dose will be applied at the clinic under the supervision of the study staff. Subjects will be instructed to apply about 1.5 ml of study drug with a dropper to the balding areas of the scalp on the vertex and the temples twice daily, once in the morning and once in the evening. Subjects will be asked to bring back all used containers of study drug and all unused study drug to each study visit. Subjects will also be given a diary, shown what things have to be recorded on it and asked to bring back the completed diary to the study center at each visit.

Conditions

  • Alopecia, Androgenetic

Interventions

  • Clascoterone 5% solutionDrug

    Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

  • Vehicle solutionDrug

    Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in non-vellus Total Area Hair Count (TAHC)Time frame: 6 months
  2. Subject's assessment of own hair coverageTime frame: 6 months

Locations

27 sites in 3 countries. Site status is shown where the registry gives one.

  • Investigate MD

    Scottsdale, Arizona

  • Physician's Institute of Cosmetic and Reconstructive Surgery

    Hollywood, Florida

  • DelRicht Research

    Atlanta, Georgia

  • Revival Research Institute

    Troy, Michigan

  • Grekin Skin Institute

    Warren, Michigan

  • DelRicht Research

    Wildwood, Missouri

  • Piedmont Plastic Surgery and Dermatology

    Huntersville, North Carolina

  • Advanced Dermatology & Cosmetic Surgery

    Spartanburg, South Carolina

  • DelRicht Research

    Thompson's Station, Tennessee

  • Austin Institute for Clinical Research

    Pflugerville, Texas

  • Acclaim Dermatology LLC

    Sugar Land, Texas

  • Premier Clinical Research

    Spokane, Washington

  • Clinical Research Center for Hair and Skin Science, Dept. of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Emovis GmbH

    Berlin, Germany

  • Privatpraxis Dr. Hilton & Partner

    Düsseldorf, Germany

  • Dermaticum-Privatpraxis für Dermatologie

    Freiburg im Breisgau, Germany

  • Eurofins | bioskin

    Hamburg, Germany

  • Department of Dermatology and Allergy, Johannes Gutenberg-Universität KöR

    Mainz, Germany

  • Centrum Medyczne Pratia

    Katowice, Poland

  • Centrum Medyczne Angelius Provita

    Katowice, Poland

  • Centrum Medyczne All-med Badania Kliniczne

    Krakow, Poland

  • Centrum Nowoczesnych Terapii Dobry Lekarz

    Krakow, Poland

  • Diamond Clinic Sp. z o.o.

    Krakow, Poland

  • Dermoklinika Centrum Medyczne s.c. M. Kierstan, J.Narbutt, A. Lesiak

    Lodz, Poland

  • Pro Life Medica

    Lublin, Poland

  • Narodowy Instytut Geriatrii, Reumatologii iRehabilitacji im. prof. dr hab. med. Eleonory Reicher

    Warsaw, Poland

  • Carpe Diem Centrum Medycyny Estetycznej

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.